Menu

Advisors to FDA Recommend Approval of Gene Therapy for Blindness

Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.

Oct 12, 2017
Jef Akst

FLICKR, HELGA BIRNA JÓNASDÓTTIRUpdate (December 19): The US Food and Drug Administration (FDA) today approved Luxturna for the treatment of an inherited form of vision loss. It is the first gene therapy approved in the U.S. to correct a specific disease-linked gene. “We’re at a turning point when it comes to this novel form of therapy,” FDA Commissioner Scott Gottlieb said in a statement. “I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses.”

A panel of 16 independent advisers to the US Food and Drug Administration (FDA) voted unanimously today (October 12) to recommend the approval of Luxturna, a gene therapy meant to treat Leber congenital amaurosis—a rare, inherited form of childhood blindness—and other retinal disorders, STAT News reports. If the agency agrees with the panel’s recommendation, Luxturna would be the first gene therapy aimed at correcting a congenital defect approved in the U.S.

The therapy, developed by Philadelphia-based Spark Therapeutics, is injected directly into the eye in a one-time treatment. Billions of virus particles deliver a functional copy of the RPE65 gene—which encodes a protein necessary for normal vision and is mutated in patients with certain vision disorders—to the retina. So far, more than two dozen children and adults with RPE65 mutations have been treated with Luxturna in the context of clinical trials, and some 93 percent of them have shown improved light sensitivity and functional vision. The effects are long lasting, with improvements continuing for at least four years in some patients that have been tracked that long.

“If my child or myself had this condition I would not hesitate for a moment getting treatment with [Luxturna],” Albert Maguire, a retinal disease specialist at Children’s Hospital of Philadelphia who led the Luxturna clinical trials, said at the advisory panel hearing today, according to STAT News.

If approved, Luxturna would be the first gene therapy that fixes an inherited genetic disorder in the U.S. (The official title of first approved gene therapy goes to Novartis’s CAR T-cell therapy, greenlighted this August.) The FDA must make its decision by January 12, 2018.

“This is what I believe medicine is going to be like for the next 20, 30, if not 50 years,” Spark CEO Jeff Marrazzo tells MIT Technology Review of these types of gene therapies. “I think this is the beginning of an age that is going to fundamentally change medicine.”

See “Targeting DNA

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.